Europäische Union - Deutsch - EMA (European Medicines Agency)

actavis group ptc ehf - reteplase - herzinfarkt - antithrombotische mittel - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - reteplasum - lyophilisat - praeparatio cryodesiccata: reteplasum 10 u., acidum tranexamicum, acidum phosphoricum, dikalii phosphas trihydricus, saccharum, polysorbatum 80, pro vitro. solvens: aqua ad iniectabilia 10 ml. - thrombolytische therapie bei akutem herzinfarkt - biotechnologika